The pharmaceutical industry is intensifying research into next-generation GLP-1 receptor agonists to address limitations of current weight-loss medications. As patent protections expire on existing treatments, major pharmaceutical companies are competing to develop improved formulations with better safety profiles and reduced adverse effects. This competitive landscape aims to expand therapeutic options for obesity management while minimizing tolerability issues that have affected patient compliance and market adoption.

Summary auto-generated by AI from the original publisher's content. Editorial standards.